421 related articles for article (PubMed ID: 16167275)
1. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
3. [The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe].
Knerr V; Gathmann B; Eades-Perner AM; Kindle G; Grimbacher B
Med Klin (Munich); 2008 Sep; 103(9):620-7. PubMed ID: 18813884
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance.
Högy B; Keinecke HO; Borte M
Eur J Health Econ; 2005 Mar; 6(1):24-9. PubMed ID: 15480920
[TBL] [Abstract][Full Text] [Related]
5. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
6. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
[TBL] [Abstract][Full Text] [Related]
7. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
8. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
Haddad É; Barnes D; Kafal A
Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
[TBL] [Abstract][Full Text] [Related]
9. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.
Gardulf A; Borte M; Ochs HD; Nicolay U;
Clin Immunol; 2008 Jan; 126(1):81-8. PubMed ID: 17964220
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
15. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID).
Bayrakci B; Ersoy F; Sanal O; Kiliç S; Metin A; Tezcan I
Turk J Pediatr; 2005; 47(3):239-46. PubMed ID: 16250308
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.
Arora R; Newton TC; Nelson MR
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):367-70. PubMed ID: 17941286
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
20. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies.
Abrahamsen TG; Sandersen H; Bustnes A
Pediatrics; 1996 Dec; 98(6 Pt 1):1127-31. PubMed ID: 8951264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
